ArticleACS chemical biology2013
Engineering unnatural variants of plantazolicin through codon reprogramming.
Article in ACS chemical biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- A Silent Biosynthetic Gene Cluster from a Methanotrophic Bacterium Potentiates Discovery of a Substrate Promiscuous Proteusin Cyclodehydratase.ACS chemical biology · 2022Article
- New developments in RiPP discovery, enzymology and engineering.Natural product reports · 2021Review
- Substrate Recognition by the Class II Lanthipeptide Synthetase HalM2.ACS chemical biology · 2020Article
- Heterologous production of coryneazolicin in Escherichia coli.The Journal of antibiotics · 2019Article
- Enzymatic Reconstitution and Biosynthetic Investigation of the Lasso Peptide Fusilassin.Journal of the American Chemical Society · 2019Article
- RiPP antibiotics: biosynthesis and engineering potential.Current opinion in microbiology · 2018Review
- A lanthipeptide library used to identify a protein-protein interaction inhibitor.Nature chemical biology · 2018Article
- Heterologous Production of Microbial Ribosomally Synthesized and Post-translationally Modified Peptides.Frontiers in microbiology · 2018Review
- Profiling of Microbial Colonies for High-Throughput Engineering of Multistep Enzymatic Reactions via Optically Guided Matrix-Assisted Laser Desorption/Ionization Mass Spectrometry.Journal of the American Chemical Society · 2017Article
- YcaO-Dependent Posttranslational Amide Activation: Biosynthesis, Structure, and Function.Chemical reviews · 2017Review
- Dissection of goadsporin biosynthesis by in vitro reconstitution leading to designer analogues expressed in vivo.Nature communications · 2017Article
- In Vitro Biosynthesis and Substrate Tolerance of the Plantazolicin Family of Natural Products.ACS chemical biology · 2016Article
- Post-translational Claisen Condensation and Decarboxylation en Route to the Bicyclic Core of Pantocin A.Journal of the American Chemical Society · 2016Article
- Combinatorial biosynthesis of RiPPs: docking with marine life.Current opinion in chemical biology · 2016Review
- Plantazolicin is an ultra-narrow spectrum antibiotic that targets theACS infectious diseases · 2016Article
- New Insights into the Biosynthetic Logic of Ribosomally Synthesized and Post-translationally Modified Peptide Natural Products.Cell chemical biology · 2016Review
- Cyclisation mechanisms in the biosynthesis of ribosomally synthesised and post-translationally modified peptides.Beilstein journal of organic chemistry · 2016Review
- Unique post-translational oxime formation in the biosynthesis of the azolemycin complex of novel ribosomal peptides fromChemical science · 2016Article
- Elucidating the Specificity Determinants of the AtxE2 Lasso Peptide Isopeptidase.The Journal of biological chemistry · 2015Article
- A prevalent peptide-binding domain guides ribosomal natural product biosynthesis.Nature chemical biology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Plantazolicin (PZN) is a polyheterocyclic natural product derived from a ribosomal peptide that harbors remarkable antibiotic selectivity for the causative agent of anthrax, Bacillus anthracis. To simultaneously establish the structure-activity relationship of PZN and the substrate tolerance of the biosynthetic pathway, an Escherichia coli expression strain was engineered to heterologously produce PZN analogues. Variant PZN precursor genes were produced by site-directed mutagenesis and later screened by mass spectrometry to assess post-translational modification and export by E. coli. From a screen of 72 precursor peptides, 29 PZN variants were detected. This analogue collection provided insight into the selectivity of the post-translational modifying enzymes and established the boundaries of the natural biosynthetic pathway. Unlike other studied thiazole/oxazole-modified microcins, the biosynthetic machinery appeared to be finely tuned toward the production of PZN, such that the cognate enzymes did not process even other naturally occurring sequences from similar biosynthetic clusters. The modifying enzymes were exquisitely selective, installing heterocycles only at predefined positions within the precursor peptides while leaving neighboring residues unmodified. Nearly all substitutions at positions normally harboring heterocycles prevented maturation of a PZN variant, though some exceptions were successfully produced lacking a heterocycle at the penultimate residue. No variants containing additional heterocycles were detected, although several peptide sequences yielded multiple PZN variants as a result of varying oxidation states of select residues. Eleven PZN variants were produced in sufficient quantity to facilitate purification and assessment of their antibacterial activity, providing insight into the structure-activity relationship of PZN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.